tbuckley/cabot-search huggingface dataset:
Leukocytoclastic Vasculitis in Association with Immunoglobulin A Myeloma
Authors: JAMES J. McMILLEN
Journal: Annals of Internal Medicine (1986)

Brief Reports1 November 1986Leukocytoclastic Vasculitis in Association with Immunoglobulin A MyelomaJAMES J. McMILLEN, M.D., STEVEN K. KRUEGER, M.D., GARY A. DYER, M.D.JAMES J. McMILLEN, M.D., STEVEN K. KRUEGER, M.D., GARY A. DYER, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-5-709 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptVarious cutaneous lesions have been associated with multiple myeloma (1). An association of multiple myeloma with vasculitis has been suggested, but the evidence is not convincing (2-4). We report the case of a patient in whom leukocytoclastic vasculitis was the presentation of IgA myeloma. The vasculitis cleared with chemotherapy but recurred with reactivation of the myeloma.In June 1980, a 58-year-old white woman presented with recurring "hive-like" lesions on her trunk and limbs. Initial examination revealed urticarial, erythematous lesions bilaterally on the upper arms and thighs. Later, various lesions including urticarial and erythematous papules, nodules, and plaques were noted. The...References1. BLUEFARB S. Cutaneous manifestations of multiple myeloma. Arch Dermatol. 1955;72:506-23. CrossrefGoogle Scholar2. MCCOMBS R. Systemic "allergic" vasculitis. JAMA. 1965;194:157-64. CrossrefGoogle Scholar3. SAMSHARVILLEWINKELMANN WDR. Necrotising vasculitis associated with lethal reticuloendothelial diseases. Br J Dermatol. 1968;80:555-60. CrossrefGoogle Scholar4. CHRISTIANSONFINE HR. Vasculitis with or without panniculitis in leukemia, lymphoma, and multiple myeloma. South Med J. 1967;60:567-72. CrossrefGoogle Scholar5. BROUETCLAUVELDANONKLEINSELIGMANN JJFMM. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med. 1974;57:775-88. CrossrefMedlineGoogle Scholar6. DUPERRAT M. Erythema elevatum diutinum associe a un myelome plasmacytaine diffus [Abstract]. Bull Soc Dermatol Syph. 1959;66:6. Google Scholar7. KATZGALLINHERTZFAUCILAWLEY SJKAT. Erythema elevatum diutinum: skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. Medicine (Baltimore). 1977;56:443-55. CrossrefGoogle Scholar8. HIGHET A. Urticarial vasculitis and IgA myeloma. Br J Dermatol. 1980;102:355-7. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Specialists of Internal Medicine St. Joseph, Missouri PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLeukocytoclastic Vasculitis and Multiple MyelomaROBERT T. MEANS JR, M.D., JOHN P. GREER, M.D., JOHN S. SERGENT, M.D., THOMAS L. MCCURLEY, M.D. 1 November 1986Volume 105, Issue 5Page: 709-710KeywordsLesionsMyelomaVasculitis Issue Published: 1 November 1986 PDF downloadLoading ...
IgE‐mediated downregulation of L‐selectin (CD62L) on lymphocytes from asthmatic patients
Authors: J. Monteseirín, E. Llamas, H. Sánchez‐Monteseirín, I. Bonilla, M. J. Camacho, J. Conde, F. Sobrino, F. Sobrino
Journal: Allergy (2001)

Background: L‐selectin (CD62L) mediates the binding of lymphocytes to high endothelial venules of peripheral lymph nodes and is also involved in leukocyte attachment to the endothelium at sites of inflammation. Although it has been demonstrated that L‐selectin is shed after lymphocyte activation, it is unknown whether the expression of L‐selectin on the surface of lymphocytes can be modulated by an IgE‐dependent mechanism or whether immunotherapy (IT) might affect this mechanism. Methods: One group of adult allergic asthmatic patients had received IT for the previous 3 years. Another similar group was not treated with IT. We challenged peripheral blood lymphocytes from both groups of asthmatic patients in vitro with an anti‐IgE antibody (Ab). Expression of L‐selectin on the lymphocyte surface was analyzed by flow cytometry, and the levels of soluble L‐selectin (sL‐selectin) on culture supernatant by ELISA. Results: L‐selectin was downregulated from the surface of lymphocytes in a time‐ and anti‐IgE antibody dose‐dependent manner (with a concomitant upregulation of shed L‐selectin in the supernatant). When lymphocytes from non‐IT asthmatic patients were cultivated with anti‐IgE Ab, a statistically significantly greater CD62L downmodulation on the lymphocyte surface was observed compared with lymphocytes from the healthy group ( P &lt;0.002) and from the IT‐asthmatic group ( P &lt;0.001). When lymphocytes from non‐IT asthmatic patients were cultivated with anti‐IgE Ab, a significantly greater sL‐selectin level in the culture supernatant was observed compared with lymphocytes from the healthy group ( P &lt;0.001) and with lymphocytes from IT‐asthmatic group ( P &lt;0.001). Conclusions: We present evidence that the expression of L‐selectin on the surface of lymphocytes can be modulated by an IgE‐dependent mechanism. This mechanism can be affected by IT.
Silly-Season Thoughts
Authors: John Lister
Journal: New England Journal of Medicine (1977)

I HEARD on the radio the other day that the weekly journal Punch was the first to describe the weeks of summer when Parliament is in recess and high society used to leave London for the South of France, or the grouse moors in Scotland, as the silly season. At that time the journalists were deprived of the source of much of their material, and so the newspapers became filled with news of many trivialities of life for which there would normally be no space. Today, although Parliament still goes into its summer recess there are not many people who . . .
“Progress” in Cancer Research — Don’t Say It Isn’t So
Authors: Daniel S. Greenberg
Journal: New England Journal of Medicine (1975)

Acknowledging that what follows is akin to a playwright reviewing his own production, your correspondent will now recount a journalistic excursion through the minefields of medical orthodoxy.I recently wrote an article in the Columbia University Journalism Review (January/February, 1975), "A Critical Look at Cancer Coverage," reprinted in the Washington Post (January 19), the thrust of it being that the lay press is unduly gullible in reporting "progress" in cancer treatment. The basis for this contention was that cancer survival rates, as reported by the National Cancer Institute (NCI), have shown little improvement over the past two decades or so, . . .
Increased Exploratory Activity and Altered Response to LSD in Mice Lacking the 5-HT5A Receptor
Authors: Régis Grailhe, Christian Waeber, Stephanie C Dulawa, Jean P Hornung, Xiaoxi Zhuang, Dani Brunner, Mark A Geyer, René Hen
Journal: Neuron (1999)

In order to determine the distribution and function of the 5-HT5A serotonin receptor subtype, we generated knockout mice lacking the 5-HT5A gene. Comparative autoradiography studies of brains of wild-type (wt) and 5-HT5A knockout (5A-KO) mice revealed the existence of binding sites with high affinity for [125I]LSD that correspond to 5-HT5A receptors and that are concentrated in the olfactory bulb, neocortex, and medial habenula. When exposed to novel environments, the 5A-KO mice displayed increased exploratory activity but no change in anxiety-related behaviors. In addition, the stimulatory effect of LSD on exploratory activity was attenuated in 5A-KO mice. These results suggest that 5-HT5A receptors modulate the activity of neural circuits involved specifically in exploratory behavior and suggest that some of the psychotropic effects of LSD may be mediated by 5-HT5A receptors.
S96 Simvastatin as an adjuvant therapy for infection and sepsis–in-vitro and in-vivo studies suggest pre-emptive / early therapy in the elderly
Authors: JM Patel, H Greenwood, G Walton, F Gao, JM Lord, E Sapey, DR Thickett
Journal: Thorax (2013)

<h3></h3> Ageing is associated with increased episodes of sepsis and poorer outcomes. Statins are associated with improved outcomes during infection. We aimed to characterise the impact of age and acute severe infection on key neutrophil functions, assess whether physiologically relevant doses of simvastatin altered neutrophil functions and if benefits were seen, when during a septic episode statins could be utilised. <h3>Methods</h3> Neutrophils from healthy volunteers and patients with lower respiratory tract infections (LRTI), pneumonia and sepsis were assessed for migratory accuracy, phagocytosis and neutrophil extracellular trap production before and after in-vitro treatment with simvastatin. Healthy elderly volunteers received 80mg simvastatin or placebo in a cross over double-blind randomised controlled trial and neutrophil functions were assessed. Data presented is for migration. <h3>Results</h3> Neutrophils from healthy subjects (n = 70, aged 21–94) demonstrated preserved neutrophil movement) (R<sup>2</sup> = -0.48, p &lt; 0.0001) towards chemoattractants (data shown for IL-8). Neutrophil chemotaxis decreased after 60yrs (comparing &lt;35 to &gt;65yrs: mean difference (MD)1.25μm/min, p = 0.02). There was a progressive decrease in neutrophil chemotaxis in old patients with a LRTI, pneumonia and severe sepsis (MD compared to healthy control; LRTI (n = 10), 0.7μm/min, p = 0.04; pneumonia (n = 5), MD1.1μm/min, p = 0.02; sepsis (n = 22) MD1.6μm/min, p = 0.01) with “septic neutrophils” unable to mount targeted chemotaxis. Improvements to baseline were seen following recovery. <i>In-vitro</i> treatment of neutrophils from healthy older people with simvastatin (1µM) restored “old” neutrophil chemotaxis to that of “young” cells. Simvastatin also restored neutrophil migration from old patients with LRTI and pneumonia to baseline but not in patients with sepsis. Two weeks of oral simvastatin 80mg once daily therapy in healthy old volunteers (Age&gt;65,n = 20) increased the accuracy of neutrophil migration (MD1.68μm/min, p = 0.02) replicating benchwork. <h3>Conclusions</h3> “Elderly” neutrophil function is compromised in health, and deteriorates during infective episodes, in accordance with the severity of the insult. Migratory accuracy can be improved with simvastatin therapy however neutrophil function in sepsis patients cannot be modulated during short term <i>in-vitro</i> therapy. Our data suggest statin therapy might be a preventative or an early adjuvant intervention rather than a treatment in established sepsis. We are testing whether simvastatin 80mg for seven days modifies neutrophil responses in elderly patients with pneumonia and sepsis (SNOOPI Trial).
ASCI: reflections on the first 100 years and a proposal for the next
Authors: William N. Kelley
Journal: Journal of Clinical Investigation (2008)

Congratulations to the ASCI and its membership on the first 100 years.From their first organizational meeting on the Boardwalk in Atlantic City in June 1907, our predecessors recognized the need for an organization for the clinician who had a strong interest in true experimental medicine.These nine Young Turks formed the Society, had their first meeting at the Willard Hotel in Washington, DC, in 1909, and went on to become some of the leaders of American medicine in the first half of the 20th century.The establishment of the JCI in 1924 further enhanced the high standards of the ASCI and its membership.Surely thousands of us have benefited from the foundation of the ASCI and the JCI, as have, I would submit, millions of patients as well.
Hematin-lnduced Hemolysis in Acute Porphyria
Authors: John M. Petersen, Claus A. Pierach
Journal: Annals of Internal Medicine (1984)

Letters and Corrections1 December 1984Hematin-lnduced Hemolysis in Acute PorphyriaJOHN M. PETERSEN, D.O., CLAUS A. PIERACH, M.D.JOHN M. PETERSEN, D.O., CLAUS A. PIERACH, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-6-877_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Although complications associated with the use of hematin have been rare, we report a case of hematin-related hemolysis in a woman with severe acute intermittent porphyria.A 32-year-old woman who had had symptomatic acute intermittent porphyria for 18 months presented with her fourth monthly episode of Porphyric neuropathy. She had severe, non-localized, lower abdominal pain requiring high-dose narcotics; resting tachycardia; fever without leukocytosis; hypertension (170/120 mm Hg); depression; urinary retention; the syndrome of inappropriate diuretic hormone secretion; and quadriparesis. An electromyogram 1 year before had shown a mild median neuropathy of the right hand with some delay...References1. LAMONFRYKHOLMHESSTSCHUDY JBRD. Hematin therapy for acute porphyria. Medicine. 1979;58:252-69. CrossrefMedlineGoogle Scholar2. DHARBOSSENMAIERCARDINALPETRYKAWATSON GIRZC. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand. 1978;203:437-43. CrossrefMedlineGoogle Scholar3. MORRISDUDLEYPEARSON DMR. Coagulopathy associated with hematin treatment for acute intermittent porphyria. Ann Intern Med. 1981;95:700-1. LinkGoogle Scholar4. GLUECKGREENCOHENTSAO RDIC. Hematin: unique effects on hemostasis. Blood. 1983;61:243-9. CrossrefMedlineGoogle Scholar5. CHOUFITCH AC. Hemolysis of mouse erythrocytes by ferriprotoporphyrin IX and chloroquine. J Clin Invest. 1980;66:856-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByDifferential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrinFerriporphyrins and endothelium: a 2-edged sword—promotion of oxidation and induction of cytoprotectantsManagement of Acute Attacks in the PorphyriasPorphyries hépatiques : stratégies diagnostiques et thérapeutiquesThe PorphyriasHeme in the treatment of heme deficiency statesDrug-induced red cell dyscrasiasReferences 1 December 1984Volume 101, Issue 6Page: 877-878KeywordsAbdominal painDiureticsElectromyographyFeversHormonesHypertensionLeukocytosisNeuropathyPorphyriaTachycardia Issue Published: 1 December 1984 PDF DownloadLoading ...
False-Positive Serologic Tests for Echinococcal Infection
Authors: Carl W. Norden, Deborah Hammond, Harvey Mendelow, Peter Schantz
Journal: Annals of Internal Medicine (1978)

Letters and Corrections1 July 1978False-Positive Serologic Tests for Echinococcal InfectionCARL W. NORDEN, M.D., DEBORAH HAMMOND, M.D., HARVEY MENDELOW, M.D., PETER SCHANTZ, V.M.D., PH.D.CARL W. NORDEN, M.D.Search for more papers by this author, DEBORAH HAMMOND, M.D.Search for more papers by this author, HARVEY MENDELOW, M.D.Search for more papers by this author, PETER SCHANTZ, V.M.D., PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-89-1-144_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Despite previous documentation (1-3), serologic testing for hydatid (echinococcal) disease, as routinely performed at the Center for Disease Control, is not widely known to yield false-positive reactions. Failure to recognize this fact may result in delays in appropriate diagnostic procedures in space-occupying lesions of the liver. The following case demonstrates this point.In May 1976 a 61-year-old black man with known Parkinson's disease was noted to have a mildly elevated alkaline phosphatase level; a radionuclide liver scan revealed a circumscribed filling defect. About one year later a repeat liver scan showed the lesion to be essentially unchanged...References1. SCHANTZ P: Testing for hydatid disease (letter). Lancet 2:1022, 1976 CrossrefMedlineGoogle Scholar2. YARZABAL L, SCHANTZ P, and LOPEZ-LEMES M: Comparative sensitivity and specificity of the Casoni intradermal and the immunoelectrophoresis tests for the diagnosis of hydatid disease. Am J Trop Med Hyg 24:842-848, 1975 CrossrefGoogle Scholar3. KAGAN I: A review of serological tests for the diagnosis of hydatid disease. Bull WHO 39:25-37, 1968 MedlineGoogle Scholar4. OKUDA K, MUSHA H, NAKAJIMA Y, KUBO Y, SNIMOKAWA Y, NAGASAKI Y, SAWA Y, JINNOUCHI S, KANEKO T, OBATA H, HISAMITSU T, MOTOIKE Y, OKAZAKI N, KOJIRO M, SAKAMOTO K, and NAKASHIMA T: Clinicopathologic features of encapsulated hepatocellular carcinoma: a study of 26 cases. Cancer 40:1240-1245, 1977 CrossrefMedlineGoogle Scholar5. VARELA-DlAZ V, GUISANTES J, RlCARDES M, YARZABAL L, and COLTORTI E: Evaluation of whole and purified hydatid fluid antigens in the diagnosis of human hydatidosis by the immunoelectrophoresis test. Am J Trop Med Hyg 24:298-303, 1975 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: CARL W. NORDEN, M.D.; DEBORAH HAMMOND, M.D.; HARVEY MENDELOW, M.D.; PETER SCHANTZ, V.M.D., PH.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDiagnostic serology of tropical parasitic diseases 1 July 1978Volume 89, Issue 1Page: 144-145KeywordsEchinococcosisInfectious disease controlLesionsLiverParkinson diseasePhosphatases ePublished: 1 December 2008 Issue Published: 1 July 1978 PDF downloadLoading ...
Lack of correlation between direct and indirect measurements of arterial pressure in unanaesthetized rats
Authors: R. D. Bunag, J. W. McCubbin, I. H. Page
Journal: Cardiovascular Research (1971)

Journal Article Lack of correlation between direct and indirect measurements of arterial pressure in unanaesthetized rats Get access Ruben D. Buñag, Ruben D. Buñag 2 From the Research Division, Cleveland Clinic Foundation, Cleveland, Ohio 44106, U.S.A. 2Present address: Department of Pharmacology, University of Kansas Medical Center, Kansas City, Kansas 66103, U.S.A. Search for other works by this author on: Oxford Academic PubMed Google Scholar James W. McCubbin, James W. McCubbin From the Research Division, Cleveland Clinic Foundation, Cleveland, Ohio 44106, U.S.A. Search for other works by this author on: Oxford Academic PubMed Google Scholar Irvine H. Page Irvine H. Page From the Research Division, Cleveland Clinic Foundation, Cleveland, Ohio 44106, U.S.A. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 5, Issue 1, January 1971, Pages 24–31, https://doi.org/10.1093/cvr/5.1.24 Published: 01 January 1971 Article history Accepted: 10 April 1970 Published: 01 January 1971
Prednisone versus Cortisone in Acute Rheumatic Fever
Authors: John L. Fischetti, William R. R. Granger
Journal: New England Journal of Medicine (1957)

IT has generally been accepted that prednisone (Metacortandralone) is three to five times as effective as cortisone and hydrocortisone, milligram for milligram.1 If this is true, this steroid, lacking properties of salt and water retention2 to the degree of older steroids, should indeed be the drug of choice in collagen disease or rheumatic fever3 when salicylates were not tolerated or efficacious.The following case is presented to demonstrate the life-saving results of cortisone when prednisone, in doses generally accepted to be more efficacious,4 failed.Case ReportA 33-year-old colored housewife was admitted to the Brooklyn Hospital on May 11, 1956, . . .
P257 A comparison of scoring systems in the management of a range of pulmonary embolism patients in a university hospital
Authors: M. Maruthappu, A. Manuel, A. Christian, A. Hollington, M. Ramsden, Z. Alexopoulou, M. Healy, M. Giles
Journal: Thorax (2010)

<h3>Introduction</h3> Pulmonary embolism (PE) is a leading cause for inpatient admission and in patient mortality in the UK. Its clinical features are often nonspecific, making a diagnosis of pulmonary embolism difficult and without appropriate treatment; a pulmonary embolism can be fatal. We compared three scoring systems (Geneva and Wells score, which are both predictive tools and Pulmonary Embolism Severity Index (PESI) a risk stratification tool) in three distinct patient groups; those whose primary cause of death was pulmonary embolism, those whose management required admission or patients managed on an outpatient basis. <h3>Methods</h3> A retrospective review of case notes for patients with the primary diagnosis of pulmonary embolism from 2009 to 2010 was performed at the Oxford Radcliffe NHS Trust, applying the Wells, PESI and Geneva scoring systems. Death from PE was defined by the presence of a PE or it being listed as the primary cause of death on the death certification in combination with concordant view of a senior clinician of the medical team. Outpatient management was based on patients having a zero length-of-stay. All groups were distinct. <h3>Results</h3> See Abstract P257 Table 1 for selected results. <h3>Discussion</h3> Across all our group of patients, the PESI outperformed both the Wells and Geneva score. Patients who died from PE were older and more hypoxic, and often caused most diagnostic difficulty presenting with non-respiratory symptoms in over half of the cases. Abnormal chest radiograms were common in all groups and although Ddimer assists in diagnosis other biomarkers such as troponin and BNP were not helpful. The PESI also outperformed the other scores as aid on deciding to manage patients with PE as an outpatient, but still with a degree of uncertainty. In conclusion, PESI should be considered in the management and risk stratification of PE and PE should be always considered in older patients with non specific clinical features, abnormal radiology and hypoxia. Managing PE as an outpatient potentially requires a combination of scoring systems in a prospective study.
Hyposensitisation with house dust mite vaccine in bronchial asthma.
Authors: J Gaddie, C Skinner, K N Palmer
Journal: BMJ (1976)

In a double-blind placebo-controlled trial of tyrosine-absorbed Dermatophagoides pteronyssinus vaccine no improvement was seen in 45 patients with asthma sensitive to house dust mite. In particular there was no significant improvement in symptom scores, spirometry, and skin and nasal challenge test results. Some patients in other studies have benefited from doses of vaccine much stronger than those now commercially available, but the incidence of side effects has also been high.